The application of SeNP in the early stages of pulmonary fibrosis led to a decrease in the level of the cytokine TGF-β1, inflammation, and alveolitis; the application of SeNP in the late stages of pulmonary fibrosis did not lead to significant results. This evidence concerns the gene TGFB1 and pulmonary fibrosis.